COLORADO SPRINGS, Colo., Oct. 23, 2013 /PRNewswire/ -- Endocan Corporation (NASDAQ OTC: XCHC) a U.S. Company specializing in cannabis and cannabinoid formulation-based health and wellness solutions, issues guidance with regard to the next phase of its new product releases and international branding campaign through the Company's marketing launch in the United States, Canada, and Europe.
Following the corporate name change to Endocan Corporation and successful launch of the www.endocan.com website, the Company enters the final stages of its new product releases through targeted marketing via licensing arrangements with State approved dispensaries, and social media outlets. The ultimate goal is to position Endocan branded products with useful education and support for those with critical ailments.
In this effort, Endocan has launched a social media campaign using FaceBook, Twitter, Google+, You Tube, and LinkedIn. The Endocan social media sites can be found on the home page or here:
In addition, the Company plans to make available to media outlets key members of the Company's management for interviews and to initiate brand building through speaking engagements, public conference calls, and a road show in early 2014. The airing of Endocan commercials in top national markets will also be used to build on brand visibility. Commercial treatments for various advertisements were prepared earlier this year, and production has been awaiting the release of the Endocan name and branding.
Endocan's management team has a high degree of media savvy. Among other individual achievements, management was involved with the critically acclaimed documentary, American Drug War 2, a Sacred Cow production, directed by Kevin Booth. The film can be seen at www.AmericanDrugWar2.com. More national and international documentary and educational releases are expected in the near future to help get the word out across the nation.
"We are very impressed with the marketing platforms modeled by the Endocan team. The Company intends to use all available media resources to share the progress of the Company and the stories of cannabis patients. Similar efforts have supported and matured many early stage companies, such as ours, into global, socially aware businesses, and we are very excited to have started that journey," stated Robert Kane, CFO & Sr VP of Business Development, Endocan Corporation.
About Endocan Corporation
The brand name Endocan™ was chosen by the Board as a direct reference to the endocannabinoid system of the human body. The endocannabinoid system is a group of neuromodulatory compounds and their receptors that are involved in a variety of fundamental physiological processes including pain-sensation, immune function, stress, sleep, mood, appetite, and memory. Cannabinoids from plants, including those found in the Cannabis genus, as well as those autonomously produced within living biological systems, work together in the operation of the endocannabinoid system. The modulation of this system is the basis for cannabinoid-based medical treatments to assist patients to improve their health and well-being.
Endocan Corporation, (FKA The X-Change Corporation) is currently developing new natural cannabinoid containing products based on innovative formulations to utilize the unique and potent benefits of the cannabis and hemp plants. Medicinal properties of cannabis, and hemp have been known and applied for thousands of years. With the aid of scientific research, Endocan Corporation is translating such knowledge into development of effective cannabinoid formulation-based health and wellness solutions as well as cosmeceutical, nutraceutical, and food brands throughout the world. The Company's health and wellness, nutritional, and cosmetics lines will address personal needs and will evolve with the introduction of new formulations and products, advancing the Company within the expanding multibillion-dollar global market.
Forward Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events, or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. The Company does not undertake any duty nor does it intend to update the results of these forward-looking statements.
CFO, Sr Vp of Business Development
SOURCE Endocan Corporation